MR analyses provided a similar central effect estimate for genetically proxied HMGCR estimates and prostate cancer as those found for PCSK9 inhibition, although with wider corresponding confidence intervals resulting in weaker evidence of an effect. The gene discussed is PCSK9; the disease is prostate carcinoma.